Insulin Aspart
Also known as: Fiasp, Fiasp Penfill, Fiasp Pumpcart, Insulin Aspart Flexpen, Insulin Aspart Penfill, Merilog, Merilog Solostar, Novolog, Novolog Penfill.
Wholesale (NADAC) cost for every strength and dosage form — the price pharmacies pay, published weekly by CMS. Not your out-of-pocket price.
Wholesale (NADAC) prices — every strength & form
| Strength | Form | NADAC / unit | Package | Class |
|---|---|---|---|---|
| 100 UNIT/ML | Pen | $8.77 / mL | $131.48 / 15 ML box | Generic |
| 100 UNIT/ML | Vial | $6.95 / mL | $69.55 / 10 ML box | Generic |
| 100 UNIT/ML | (unspecified) | $8.57 / mL | — | Brand |
Wholesale (NADAC) — the price pharmacies pay, not your out-of-pocket price. Brand list prices fall after confidential rebates. Liquids, creams, and sprays are priced per mL or gram; a typical package may be a bottle or tube (size not set yet). Box prices are per full package where the size is known.
NADAC week of 2026-07-01 · updated weekly · source CMS
Medicaid & Medicare spending · 2024
In 2024, Medicaid paid $207,057,604 gross for Insulin Aspart across 991,878 prescriptions (measured, national).
Medicare Part D EST spent an estimated ~$55,814,581 gross (retail pharmacy only; excludes Part B).
Gross program spending, before rebates — not what patients pay out of pocket. Brand net cost is materially lower after confidential rebates; generics are close to net.
Source: Medicaid SDUD 2024 · Medicare Part D 2024 · CMS